CDMO / CMOFounded 1897
Lonza Group AG
Basel, Basel-Stadt, Switzerland
One of the largest CDMOs in the world, providing development and GMP manufacturing of biologics (monoclonal antibodies, cell and gene therapies) and small-molecule APIs across a network of more than 30 sites spanning five continents.
- Segment
- CDMO / CMO
- Headquarters
- Basel, Basel-Stadt, Switzerland
- Founded
- 1897
- Website
- www.lonza.com
Notable facts
- Founded in 1897 as a hydroelectric chemical plant in Gampel, Switzerland, and is now headquartered in Basel — frequently cited in industry coverage as the original CDMO.
- Supplied roughly two-thirds of the raw materials used to manufacture Moderna's COVID-19 vaccine at its US and Swiss facilities during the pandemic.
- Reported 2023 revenue of CHF 6.72 billion with about 18,000 employees.
- In 2024 announced plans to divest its Capsules & Health Ingredients segment to focus fully on CDMO (biologics, small molecule, cell & gene therapy) operations.
Sourcing guides
Sources. This profile is compiled from public reference data, WebSearch-verified against source 1 · source 2. Data as of 2026-07-14. See methodology.
Sourcing a vendor in this segment today? We connect clinical operations, regulatory, and procurement teams with qualified cdmo / cmo vendors.
Request vendors